Clinical Trials Browser

Completed × Observational × Lenalidomide × Clear all

NCT07206810 2025-10-03

A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients

Neoplasms, Plasma Cell

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Multiple Myeloma, Recurrence

NCT03098589 2025-03-30

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Head & NeckLymphoidOther hematologic neoplasm

Sleepiness, Arrhythmias, Cardiac, Cataract, Confusion, Coronary Artery Disease, Digestive System Diseases, Dizziness, Fatigue, Heart Failure, Hemorrhage, Hypersensitivity, Hypotension, Orthostatic, Hypothyroidism, Infections, Lymphoma, Peripheral Nervous System Diseases, Seizures, Thromboembolism, Tumor Lysis Syndrome, Neoplasms, Second Primary, Lung Diseases, Interstitial, Renal Insufficiency, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Teratogenesis

NCT04036448 2025-03-11

RevlimidPMS

LymphoidMyeloid

Lymphoma, Follicular, Myelodysplastic Syndromes, Recurrence, Lymphoma, Mantle-Cell

NCT03647124 2025-03-04

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Recurrence, Lymphoma, Mantle-Cell

NCT02692339 2022-06-30

PrObe-L

Multiple Myeloma

NCT01752075 2019-11-18

A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan

Multiple Myeloma

NCT02556905 2017-12-04

A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea

Multiple Myeloma